News
GSK provides update on feladilimab, an investigational inducible T cell co-stimulatory (ICOS) agonist.
GlaxoSmithKline plc announced, following a recommendation by the Independent Data Monitoring Committee, that it has taken the decision to stop enrolling patients in the phase II INDUCE-3 trial , including discontinuing treatment with feladilimab.
The INDUCE-3 study is investigating feladilimab in combination with pembrolizumab versus placebo in combination with pembrolizumab in patients with PD-L1 positive recurrent locally advanced or metastatic head and neck squamous cell carcinoma. GSK has also made the decision to stop the INDUCE-4 phase II trial, a study investigating feladilimab versus placebo in combination with pembrolizumab and chemotherapy.
Condition: Head & Neck Cancer
Type: drug